Crestor Side Effects: Incidence Rates Across Clinical Trials

What the Prescribing Label Says About Adverse Event Rates

The FDA-approved prescribing label for rosuvastatin is the regulatory floor for safety disclosure. Reading it numerically, rather than scanning warning boxes, gives the clearest picture of what trial participants actually experienced.

In placebo-controlled trials of 5 to 40 mg rosuvastatin, adverse reactions reported at a rate of 2% or more and at a rate greater than placebo included: myalgia (3.6% vs. 3.1% placebo), constipation (2.8% vs. 2.4%), asthenia (2.8% vs. 2.5%), abdominal pain (2.4% vs. 1.9%), and nausea (2.2% vs. 2.1%). [1] Those are modest absolute differences, but the myalgia signal persists across higher doses and specific subgroups.

Hepatic transaminase elevations greater than three times the upper limit of normal occurred in 0.4% of patients receiving 40 mg daily, compared with 0.1% on lower doses. [1] The FDA does not require routine liver enzyme monitoring during statin therapy unless symptoms suggest hepatic involvement, a position consistent with 2013 ACC/AHA cholesterol guideline recommendations. [2]

Creatine Kinase Elevations

Asymptomatic CK elevation greater than 10 times the upper limit of normal appeared in approximately 0.1% of patients in controlled trials. [1] Symptomatic patients with CK elevation should stop the drug immediately. The 40 mg dose carries a boxed-level reminder that it should only be used when lower doses have proven insufficient, specifically because muscle toxicity risk scales with dose.

Proteinuria Signal at High Doses

Dipstick proteinuria of 2+ or greater occurred in 0.7% of patients on 40 mg vs. 0.3% on 10 mg. [1] This effect has not been shown to progress to clinically significant renal impairment, and the mechanism appears to be tubular rather than glomerular, but it does argue for avoiding the 40 mg dose in patients with pre-existing chronic kidney disease stages 3b or beyond.

JUPITER Trial: The Landmark Safety Dataset

JUPITER (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) enrolled 17,802 adults with LDL below 130 mg/dL but elevated high-sensitivity CRP (≥2 mg/L), randomized to rosuvastatin 20 mg or placebo, with a median follow-up of 1.9 years before early termination for efficacy. [3]

Cardiovascular Efficacy Context

The trial's primary cardiovascular findings are well known: a 44% reduction in the composite endpoint of MI, stroke, arterial revascularization, hospitalization for unstable angina, or cardiovascular death (HR 0.56; 95% CI 0.46 to 0.69; P<0.00001). [3] That efficacy backdrop matters when reading the adverse event data below, because any absolute risk increase from rosuvastatin must be weighed against a substantial cardiovascular benefit.

New-Onset Diabetes in JUPITER

Physician-reported diabetes occurred in 270 rosuvastatin participants vs. 216 placebo participants, a relative risk increase of 25% (HR 1.25; 95% CI 1.05 to 1.49). [3] A subsequent reanalysis by Ridker et al. Published in The Lancet estimated the risk increase at 27% when using a stricter adjudication algorithm. [4] In absolute terms, this translated to approximately 54 excess cases of diabetes per 17,802 participants over a median 1.9 years, or roughly 3 additional cases per 1,000 patient-years.

The FDA added a class label update in 2012 noting that "increases in HbA1c and fasting serum glucose levels have been reported with HMG-CoA reductase inhibitors." [1] Patients already meeting criteria for pre-diabetes (fasting glucose 100 to 125 mg/dL) appear to account for the majority of conversion events, suggesting the drug accelerates progression rather than creating de novo risk. [4]

Myopathy and Rhabdomyolysis in JUPITER

Myalgia was reported in 220 of 8,901 (2.5%) rosuvastatin participants vs. 210 of 8,901 (2.4%) placebo participants, a non-significant difference. [3] Rhabdomyolysis occurred in zero rosuvastatin patients and one placebo patient during the trial. That near-zero rate in a controlled setting is consistent with the broader post-market picture discussed below.

METEOR Trial: Atherosclerosis Progression and Tolerability

METEOR (Measuring Effects on Intima-Media Thickness: an Evaluation of Rosuvastatin) randomized 984 low-risk adults aged 45 to 70 with subclinical carotid atherosclerosis to rosuvastatin 40 mg or placebo for 104 weeks. [5]

Adverse Events at the 40 mg Dose

At the highest approved dose over two full years, the overall adverse event profile was comparable to placebo. Serious adverse events occurred in 10.6% of rosuvastatin participants vs. 11.7% of placebo participants. Myalgia occurred in 12.7% vs. 12.1%, a non-significant difference at P = 0.75. [5] CK elevation greater than 10 times the upper limit of normal was seen in 0.2% of the rosuvastatin arm vs. 0% placebo, consistent with the label figure.

Renal Findings at 40 mg

Hematuria and proteinuria were each numerically higher in the rosuvastatin arm but did not progress to renal events requiring discontinuation in any participant. [5] The authors concluded the 40 mg dose was acceptably safe over two years in this low-cardiovascular-risk population, though they noted the importance of baseline renal function screening.

CORONA Trial: Safety in Systolic Heart Failure

CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure) enrolled 5,011 adults aged 60 or older with ischemic systolic heart failure and randomized them to rosuvastatin 10 mg vs. Placebo for a median 32.8 months. [6] This trial is particularly informative because it tested a population at elevated baseline risk for drug toxicity.

Key Adverse Event Findings

The rate of elevated CK greater than 10 times the upper limit of normal was 0.2% in the rosuvastatin group vs. 0.1% in the placebo group, consistent with other trials. Hepatic enzyme elevations greater than three times the upper limit of normal occurred in 1.0% (rosuvastatin) vs. 0.6% (placebo), the highest hepatic rate seen across the major trials but still below the threshold that triggered liver-function monitoring requirements. [6]

Importantly, the trial did not show a reduction in the primary cardiovascular endpoint (fatal or non-fatal MI, stroke, or cardiovascular death), a reminder that rosuvastatin's benefit-risk calculation differs by indication.

FAERS and Post-Market Surveillance Data

The FDA Adverse Event Reporting System (FAERS) contains spontaneous reports for rosuvastatin since its 2003 approval. Spontaneous reports are inherently under-reported and cannot produce true incidence rates, but they identify signals worth monitoring.

Rhabdomyolysis Signal

Through the end of 2022, FAERS contained 1,847 reports of rhabdomyolysis associated with rosuvastatin. [7] Given cumulative prescription volume exceeding 400 million scripts in the United States alone, this produces a reporting rate well below 1 per 100,000 prescriptions. Risk factors identified in case reports include: concomitant use of gemfibrozil (which raises rosuvastatin AUC by approximately 2-fold), cyclosporine, and high-dose niacin. [1] Gemfibrozil co-administration is specifically contraindicated in the label.

Autoimmune Necrotizing Myopathy

A lower-frequency but clinically serious post-market signal is statin-associated autoimmune necrotizing myopathy (SANM), characterized by anti-HMGCR antibodies. A 2021 cohort study in JAMA Neurology estimated a class incidence of approximately 2 to 3 cases per 100,000 statin-users per year, with rosuvastatin carrying a rate consistent with the class average. [8] Unlike typical statin myalgia, SANM does not resolve on drug discontinuation and typically requires immunosuppression.

Peripheral Neuropathy Reports

FAERS contains scattered reports of peripheral neuropathy linked to rosuvastatin, though a 2014 systematic review in the European Journal of Clinical Pharmacology found the absolute signal modest and confounded by diabetes as a common indication for statin use. [9] The FDA label does not currently list peripheral neuropathy as a labeled adverse event for rosuvastatin specifically.

Comparative Muscle Toxicity Across the Statin Class

Understanding rosuvastatin's muscle risk requires context within the class. A 2022 Cochrane meta-analysis of 312 randomized controlled trials (N>285,000) found that statin-associated muscle symptoms (SAMS) pooled across the class occurred in approximately 7% of participants, but placebo-controlled trials showed only a 1% absolute excess over placebo, suggesting nocebo effect explains a meaningful share. [10]

Rosuvastatin's muscle toxicity profile compares favorably to cerivastatin (withdrawn in 2001 for excess rhabdomyolysis) and comparably to atorvastatin at equivalent LDL-lowering doses. The 2022 ACC Expert Consensus Decision Pathway on SAMS notes that rosuvastatin 5 to 10 mg every other day is an acceptable strategy for patients with confirmed prior statin intolerance, specifically because its long half-life of approximately 19 hours still provides meaningful LDL reduction on a non-daily schedule. [11]

Dose-Response for Muscle Events

The dose-response relationship for myopathy is log-linear. Moving from rosuvastatin 10 mg to 40 mg does not double CK risk in a simple proportional sense. The METEOR data suggest CK elevations greater than 10 times the upper limit of normal occur at roughly 0.2% at 40 mg vs. Approximately 0.05% at 5 to 10 mg across label data, representing a 4-fold increase in that specific endpoint over a 4-fold dose increase. [5] Patients on 40 mg with unexplained muscle pain should have CK checked within 1 week of symptom onset.

Asian Patient Pharmacokinetics

Asian patients show approximately double the plasma exposure (AUC) of rosuvastatin compared to non-Asian patients at the same dose. [1] The FDA label specifically recommends initiating at 5 mg daily in Asian patients, and the 40 mg dose should be avoided in this group. This is not a theoretical caution: the pharmacokinetic difference is consistent with a genuine doubling of muscle toxicity risk at standard doses.

Diabetes Risk: Mechanistic Context and Clinical Significance

The 25 to 27% relative risk increase for new-onset diabetes seen in JUPITER deserves nuanced interpretation. The 2010 Sattar et al. Meta-analysis published in The Lancet pooled 13 statin trials (N=91,140) and found a 9% increased odds of new-onset diabetes across the class (OR 1.09; 95% CI 1.02 to 1.17), with more intensive statin regimens carrying higher risk than moderate-intensity ones. [12]

Rosuvastatin 20 mg (as used in JUPITER) is an intensive regimen by ACC/AHA classification. The mechanism likely involves HMG-CoA reductase inhibition reducing isoprenoid flux into beta-cell cholesterol pathways, impairing glucose-stimulated insulin secretion. [4]

The clinical calculus, articulated by the 2013 ACC/AHA guidelines, is that "the risk of developing diabetes is small compared to the overall benefit of statin therapy in high-risk patients." [2] A patient with 10-year ASCVD risk above 7.5% who initiates rosuvastatin 20 mg gains cardiovascular protection that, on a population level, substantially exceeds the diabetes-related cardiovascular risk incurred by roughly 3 additional diabetes cases per 1,000 patient-years.

For patients in the pre-diabetes range (fasting glucose 100 to 125 mg/dL or HbA1c 5.7 to 6.4%), initiating rosuvastatin at 10 mg rather than 20 mg where the LDL target allows it is a reasonable strategy that may attenuate glycemic progression without sacrificing most of the cardiovascular benefit.

Hepatic Safety: Reframing the Risk

Pre-2012, statin prescribing was clouded by concern over hepatotoxicity, and clinicians commonly ordered serial liver function tests. The FDA's 2012 label change removed the routine monitoring recommendation after concluding that "serious liver injury with statins is rare and unpredictable, and routine monitoring of liver enzymes does not appear to detect or prevent serious liver injury." [1]

Transaminase Elevation Data

Across the rosuvastatin clinical development program, alanine aminotransferase (ALT) greater than three times the upper limit of normal occurred in 0.4% of patients on 40 mg, 0.2% on 20 mg, and 0.1% on 5 to 10 mg. [1] These elevations were typically transient and asymptomatic. Clinically significant drug-induced liver injury (DILI) meeting Hy's Law criteria, defined as ALT greater than three times the upper limit of normal plus bilirubin greater than two times the upper limit of normal, has been documented in isolated case reports but does not appear in the randomized trial datasets at quantifiable rates.

Fatty Liver Disease Considerations

Non-alcoholic fatty liver disease (NAFLD) was historically considered a contraindication to statin use. Current evidence reverses this: a 2020 meta-analysis in the Journal of Hepatology found statins including rosuvastatin reduced liver stiffness and transaminase levels in NAFLD patients and did not worsen histology. [13] Patients with compensated cirrhosis may still use rosuvastatin with hepatic monitoring, but decompensated liver disease remains a contraindication.

Renal Effects: Proteinuria Without Functional Loss

The proteinuria signal at 40 mg (0.7% dipstick ≥2+) prompted extensive evaluation during rosuvastatin's FDA review. Mechanistic studies showed the effect occurs in the proximal tubule, where rosuvastatin inhibits megalin-mediated albumin reabsorption, rather than through glomerular damage. [1]

Long-term renal outcomes data are reassuring. In JUPITER, estimated GFR did not decline significantly more in the rosuvastatin arm vs. Placebo over 1.9 years. [3] A 2016 observational study in the American Journal of Kidney Diseases (N=43,823) found rosuvastatin users had lower rates of CKD progression than non-statin controls after propensity matching, likely reflecting the anti-inflammatory and lipid-lowering effects on renal vasculature. [14]

Drug Interactions That Amplify Adverse Event Risk

Several co-medications predictably raise rosuvastatin plasma levels and consequently raise adverse event risk. The prescribing label specifies the following interaction-related dose limits: [1]

• Cyclosporine: limit rosuvastatin to 5 mg daily (AUC increase ~10-fold)
• Gemfibrozil: contraindicated (AUC increase ~2-fold, additive myopathy risk)
• Atazanavir/ritonavir or lopinavir/ritonavir: limit to 10 mg daily
• Simeprevir: limit to 10 mg daily
• Regorafenib: avoid combination

Aluminum and magnesium-containing antacids reduce rosuvastatin bioavailability by approximately 50% when taken simultaneously; spacing by at least 2 hours mitigates this effect.

Clinical Monitoring Recommendations

The 2018 AHA/ACC Multi-Society guideline on blood cholesterol management recommends the following safety-oriented practices for patients on rosuvastatin: [15]

1. Baseline fasting lipid panel, ALT, and fasting glucose before initiating therapy.
2. Repeat lipid panel at 4 to 12 weeks after initiation or dose change.
3. No routine CK monitoring unless symptoms of myopathy appear.
4. Annual fasting glucose or HbA1c in patients with pre-diabetes risk factors.
5. Reassess adherence and tolerability at each clinic visit.

The guideline states directly: "Routine monitoring of hepatic transaminases is not recommended. Measure hepatic function if symptoms suggest hepatotoxicity." [15]

For patients reporting muscle symptoms, the practical clinical algorithm is: obtain CK within one week, hold the drug if CK exceeds 10 times the upper limit of normal or if symptoms are severe, and rechallenge at a lower dose or alternate day schedule after 2 to 4 weeks of symptom resolution.